Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance.
The association of pulmonary hypertension with an increased risk for kidney failure in older adults with chronic kidney disease is a novel finding.
The researchers’ goals included determining how postoperative residual pulmonary hypertension was related to longitudinal mortality in patients with severe mitral regurgitation who had mitral valve surgery.
Invasive assessment of cardiopulmonary hemodynamics may predict survival after transcatheter tricuspid edge-to-edge valve repair in patients with severe tricuspid regurgitation and symptomatic heart failure.
Elevated pulmonary artery systolic pressure was found to be associated with a worse prognosis in patients with heart failure with severe secondary mitral regurgitation.
The 6th WSPH Task Force on Hemodynamic Definitions and Clinical Classification recently proposed reducing the diagnostic mPAP threshold for pulmonary hypertension.
Echocardiographic surrogate for pulmonary arterial capacitance may independently predict mortality in pulmonary hypertension.
Implantation of the endovascular device Aria during right heart catheterization was found to favorably alter pulmonary circulation in patients with pulmonary arterial hypertension.
Metformin was found to be well-tolerated and safe for the treatment of pulmonary atrial hypertension.
